CN113813265A - 灵芝酸a在治疗银屑病药物中的应用 - Google Patents
灵芝酸a在治疗银屑病药物中的应用 Download PDFInfo
- Publication number
- CN113813265A CN113813265A CN202111264465.4A CN202111264465A CN113813265A CN 113813265 A CN113813265 A CN 113813265A CN 202111264465 A CN202111264465 A CN 202111264465A CN 113813265 A CN113813265 A CN 113813265A
- Authority
- CN
- China
- Prior art keywords
- ganoderic acid
- medicament
- chloroform
- treating psoriasis
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 title claims abstract description 53
- BSEYIQDDZBVTJY-UHFFFAOYSA-N Ganoderic acid A Natural products CC(CC(=O)CCC1CC(O)C2(C)C3=C(C(=O)CC12C)C4(C)CCC(=O)C(C)(C)C4CC3O)C(=O)O BSEYIQDDZBVTJY-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 title claims description 30
- 241000222336 Ganoderma Species 0.000 claims abstract description 12
- 238000000605 extraction Methods 0.000 claims abstract description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 27
- 238000002386 leaching Methods 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 229930182735 Ganoderic acid Natural products 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000012043 crude product Substances 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 230000000073 effect on psoriasis Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000011124 aluminium ammonium sulphate Nutrition 0.000 description 1
- LCQXXBOSCBRNNT-UHFFFAOYSA-K ammonium aluminium sulfate Chemical compound [NH4+].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O LCQXXBOSCBRNNT-UHFFFAOYSA-K 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了灵芝酸A在治疗银屑病中的应用以及灵芝酸A的提取方法,灵芝酸A直接从灵芝中提取获得,成分天然,无毒,无副作用,且灵芝酸对于银屑病有显著的治疗作用,可长期使用。
Description
技术领域
本发明属于银屑病治疗技术领域,具体涉及灵芝酸A在治疗银屑病药物中的应用。
背景技术
银屑病俗称“牛皮癣”,是一种常见的高复发性皮肤疾病。银屑病具有病程长、迁延难愈等特点,严重时可致残甚至危及患者生命,给患者造成生理-心理的双重负担。然而,银屑病的发病机制复杂,时至今日临床仍无根治性药物可用。
目前银屑病的口服及外用药物以阻断过度活化的免疫系统为主,但仍有少部分银屑病患者对现有的生物制剂响应轻微、无效或伴随严重不良反应,大部分治疗有效的患者存在停药复发、继发耐药的问题,由于上述药物均只能暂时来缓解银屑病症状,且继发感染、肝肾功能损伤等毒副作用大,价格昂贵,难以长期维持,故寻找一种可长期维持的使用,同时可调节过度活化的免疫系统的药物迫在眉睫。
发明内容
为了解决上述技术问题,本发明提供了利用灵芝酸A治疗银屑病,药物成分天然无毒害,效果显著。
为了达到上述技术效果,本发明是通过以下技术方案实现的:
灵芝酸A在治疗银屑病药物中的应用;
优选的,所述药物为口服类药物;
优选的,所述口服类药物包括颗粒剂、胶囊、片剂;
优选的,所述药物为外用类药物;
优选的,所述外用类药物包括软膏剂、乳膏剂、霜剂;
优选的,所述灵芝酸A的提取方法,包括以下步骤:
S1:取灵芝在烘干机中进行充分干燥;
S2:将干燥后的灵芝用粉碎机进行粉碎至200-300目;
S3:将粉碎后的灵芝粉末用乙醇水溶液浸提3次,每次取浸提液,最后一次合并3次浸提液;
S4:将S3中得到的浸提液在温度为60-70°,压力为-0.1MPa条件下减压浓缩得到灵芝酸浸膏;
S5:将S4中的灵芝酸浸膏与水按照1:5-1:7的比例进行混合,得到混合液,然后加入混合液质量5%的NaHCO3,搅拌均匀后过滤,滤液用质量百分比浓度为10%的盐酸水溶液调PH值为2;
S6:将S5中PH值为2的滤液用5倍体积的氯仿萃取3次,每次均取氯仿层,合并3次的氯仿层;在温度40-50°,压力为-0.1MPa条件下浓缩得浓缩液;
S7:将S6所得浓缩液用硅胶柱进行纯化,以氯仿作为装柱溶剂,氯仿:丙酮体积比为10:1-3:1梯度冲洗,收集得到灵芝酸A粗品;
S8:在LH-20常压凝胶柱上,用质量百分比浓度为51%的甲醇水溶液对灵芝酸A粗品将其全部洗脱,然后在温度40°,压力为-0.1MPa下浓缩至干,得到纯度为99%以上的灵芝酸A;
S9:将S8得到的99%的灵芝酸A用氯仿溶解,再加入甲醇,在4°条件下放置至其有白色晶体析出,过滤,得到灵芝酸A。
本发明的有益效果是:
本发明利用灵芝酸A治疗银屑病,灵芝酸A直接从灵芝中提取获得,成分天然,无毒害,不会对人体造成毒副作用,且灵芝酸对于银屑病有显著的治疗作用;无毒,可长期维持服用,不易复发。
附图说明
图1是动物实验结果实物图片;
图2是HE染色切片观察结果图;
图3是细胞实验结果数据统计图。
具体实施方式
为了进一步体现本发明的方案及作用效果,下面通过具体实施例来详细说明。
实施例1
灵芝酸A在治疗银屑病药物中的应用;
优选的,所述药物为乳膏剂。
实施例2
灵芝酸A的提取方法,包括以下步骤:
S1:取灵芝在烘干机中进行充分干燥;
S2:将干燥后的灵芝用粉碎机进行粉碎至200目;
S3:将粉碎后的灵芝粉末用乙醇水溶液浸提3次,每次取浸提液,最后一次合并3次浸提液;
S4:将S3中得到的浸提液在温度为60°,压力为-0.1MPa条件下减压浓缩得到灵芝酸浸膏;
S5:将S4中的灵芝酸浸膏与水按照1:5的比例进行混合,得到混合液,然后加入混合液质量5%的NaHCO3,搅拌均匀后过滤,滤液用质量百分比浓度为10%的盐酸水溶液调PH值为2;
S6:将S5中PH值为2的滤液用5倍体积的氯仿萃取3次,每次均取氯仿层,合并3次的氯仿层;在温度50°,压力为-0.1MPa条件下浓缩得浓缩液;
S7:将S6所得浓缩液用硅胶柱进行纯化,以氯仿作为装柱溶剂,氯仿:丙酮体积比为10:1-3:1梯度冲洗,收集得到灵芝酸A粗品;
S8:在LH-20常压凝胶柱上,用质量百分比浓度为51%的甲醇水溶液对灵芝酸A粗品将其全部洗脱,然后在温度40°,压力为-0.1MPa下浓缩至干,得到纯度为99%以上的灵芝酸A;
S9:将S8得到的99%的灵芝酸A用氯仿溶解,再加入甲醇,在4°条件下放置至其有白色晶体析出,过滤,得到灵芝酸A。
实施例3
为了进一步验证实施例1中含有灵芝酸A的乳膏剂对银屑病的治疗作用,设计以下动物实验;
银屑病动物模型制作:选取6-8周龄,体重约18-20g,雌鼠40只,饲养于标准的清洁级动物饲养室;将小鼠用脱毛膏脱毛,脱毛面积为2cm*4cm;
将5%咪喹莫特乳膏按照62.5mg/只的剂量均匀涂抹于脱毛部位,持续5-7天,银屑病小鼠成模;
实验分组:正常对照组、银屑病组、银屑病+溶剂对照组,银屑病+灵芝酸A处理组;每组10只小鼠;
实验方法:灵芝酸A灌胃,2mg/kg,每日1次,正常对照组不予处理,溶剂对照组给予等量的溶剂,不加药。
实验结果:结果如图1所示,其中a为正常对照组,b为银屑病无处理组,c为银屑病+溶剂对照组,d为银屑病+灵芝酸A组;
银屑病无处理组:患部皮肤有明显成片红斑,鳞屑脱落多,大面积显著角化过度,棘层肥厚,皮表异常褶皱;
银屑病+溶剂对照组:较银屑病组无明显差异;
银屑病+灵芝酸A组:患部皮肤红斑基本消退,皮褶厚度变薄,鳞屑减少。
实施例4
细胞切片染色实验;
实验试剂:固定液:95%乙醇和冰丙酮;苏木精染液:称取苏木精0.5g,铵矾24g溶于70ml蒸馏水中,称取NaCl31g,水5ml,再加入甘油30ml和冰醋酸2ml,混合均匀,过滤,取滤液得苏木精染液;伊红染液:称取0.5g水溶性伊红染液,溶于100ml蒸馏水中;稀盐酸乙醇溶液:用75%乙醇配制1%盐酸;
实验准备:取各组小鼠背部皮肤,制成切片;
实验步骤:S1:石蜡切片脱蜡:依次将切片放入二甲苯I10min-二甲苯Ⅱ10min-无水乙醇Ⅰ5min-无水乙醇Ⅱ5min-95%酒精5min-90%酒精5min-80%酒精5min-70%酒精5min-蒸馏水洗;
S2:苏木素染细胞核:切片入Harris苏木素染3-8min,自来水洗,1%的盐酸酒精分化数秒,自来水冲洗,0.6%氨水返蓝,流水冲洗;
S3:伊红染细胞质:切片入伊红染液中染色1-3min;
S4:脱水封片:将切片依次放入95%酒精I 5min-95%酒精II 5min-无水乙醇Ⅰ5min-无水乙醇Ⅱ5min-二甲苯Ⅰ5min-二甲苯Ⅱ5min中脱水透明,将切片从二甲苯拿出来稍晾干,中性树胶封片;
S5:显微镜镜检,图像采集分析;
实验结果:如图2所示,其中a为正常对照组,b为银屑病无处理组,c为银屑病+软膏组,d为银屑病+灵芝酸A组;
切片结果分析:银屑病组表皮明显增厚,真皮层炎性细胞浸润明显,经灵芝酸A治疗后,表皮增殖明显改善,炎性细胞浸润减少(如图2中箭头所指方向)。
实施例5
细胞实验;
实验准备:取永生化人Hacat角质形成细胞,用不同的灵芝酸A进行干预(5μM/10μM/20μM/40μM)
实验方法:复苏人Hacat角质形成细胞,待长势良好时,种板,96孔板,每板5000个细胞,将培养皿置CO2培养箱内,5%CO2,37℃静置培养24小时后,加入不同浓度的灵芝酸A培养液,继续培养24小时,去除培养液,用CCK8后再孵育1-3小时,450nm度数,检测灵芝酸A对角质形成细胞增殖的抑制作用。
实验结果:如图3所示,灵芝酸A可明显抑制角质形成细胞的增殖,且呈浓度依赖性。
结果分析:灵芝酸A可明显抑制角质形成细胞的增殖。
Claims (6)
1.灵芝酸A在治疗银屑病药物中的应用。
2.根据权利要求1所述灵芝酸A在治疗银屑病药物中的应用,其特征在于,所述所述药物为口服类药物。
3.根据权利要求2所述灵芝酸A在治疗银屑病药物中的应用,其特征在于,所述口服类药物包括颗粒剂、胶囊、片剂。
4.根据权利要求1所述灵芝酸A在治疗银屑病药物中的应用,其特征在于,所述药物为外用类药物。
5.根据权利要求4所述灵芝酸A在治疗银屑病药物中的应用,其特征在于,所述外用类药物包括软膏剂、乳膏剂、霜剂。
6.根据权利要求1所述灵芝酸A在治疗银屑病药物中的应用,其特征在于,所述灵芝酸A的提取方法,其特征在于,包括以下步骤:
S1:取灵芝在烘干机中进行充分干燥;
S2:将干燥后的灵芝用粉碎机进行粉碎至200-300目;
S3:将粉碎后的灵芝粉末用乙醇水溶液浸提3次,每次取浸提液,最后一次合并3次浸提液;
S4:将S3中得到的浸提液在温度为60-70°,压力为-0.1MPa条件下减压浓缩得到灵芝酸浸膏;
S5:将S4中的灵芝酸浸膏与水按照1:5-1:7的比例进行混合,得到混合液,然后加入混合液质量5%的NaHCO3,搅拌均匀后过滤,滤液用质量百分比浓度为10%的盐酸水溶液调PH值为2;
S6:将S5中PH值为2的滤液用5倍体积的氯仿萃取3次,每次均取氯仿层,合并3次的氯仿层;在温度40-50°,压力为-0.1MPa条件下浓缩得浓缩液;
S7:将S6所得浓缩液用硅胶柱进行纯化,以氯仿作为装柱溶剂,氯仿:丙酮体积比为10:1-3:1梯度冲洗,收集得到灵芝酸A粗品;
S8:在LH-20常压凝胶柱上,用质量百分比浓度为51%的甲醇水溶液对灵芝酸A粗品将其全部洗脱,然后在温度40°,压力为-0.1MPa下浓缩至干,得到纯度为99%以上的灵芝酸A;
S9:将S8得到的99%的灵芝酸A用氯仿溶解,再加入甲醇,在4°条件下放置至其有白色晶体析出,过滤,得到灵芝酸A。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111264465.4A CN113813265A (zh) | 2021-10-28 | 2021-10-28 | 灵芝酸a在治疗银屑病药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111264465.4A CN113813265A (zh) | 2021-10-28 | 2021-10-28 | 灵芝酸a在治疗银屑病药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113813265A true CN113813265A (zh) | 2021-12-21 |
Family
ID=78918985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111264465.4A Pending CN113813265A (zh) | 2021-10-28 | 2021-10-28 | 灵芝酸a在治疗银屑病药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113813265A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104031107A (zh) * | 2014-05-26 | 2014-09-10 | 上海应用技术学院 | 一种从灵芝中提取灵芝酸a的方法 |
JP2016013981A (ja) * | 2014-07-01 | 2016-01-28 | 国立大学法人九州大学 | チューブリン重合活性調節剤、これを含む食品および薬剤、並びにチューブリン重合活性調節剤の製造方法 |
US20210290710A1 (en) * | 2020-02-26 | 2021-09-23 | Industrial Technology Research Institute | Composition for modulating intestinal permeability and/or treating and/or preventing leaky gut related diseases, and method for modulating intestinal permeability and/or treating and/or preventing leaky gut related diseases |
CN113491701A (zh) * | 2020-04-06 | 2021-10-12 | 韩国科学技术研究院 | 含灵芝酸的特应性、牛皮癣或皮肤炎症的治疗、预防或减轻用组合物及其制备方法 |
-
2021
- 2021-10-28 CN CN202111264465.4A patent/CN113813265A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104031107A (zh) * | 2014-05-26 | 2014-09-10 | 上海应用技术学院 | 一种从灵芝中提取灵芝酸a的方法 |
JP2016013981A (ja) * | 2014-07-01 | 2016-01-28 | 国立大学法人九州大学 | チューブリン重合活性調節剤、これを含む食品および薬剤、並びにチューブリン重合活性調節剤の製造方法 |
US20210290710A1 (en) * | 2020-02-26 | 2021-09-23 | Industrial Technology Research Institute | Composition for modulating intestinal permeability and/or treating and/or preventing leaky gut related diseases, and method for modulating intestinal permeability and/or treating and/or preventing leaky gut related diseases |
CN113491701A (zh) * | 2020-04-06 | 2021-10-12 | 韩国科学技术研究院 | 含灵芝酸的特应性、牛皮癣或皮肤炎症的治疗、预防或减轻用组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102389385B (zh) | 马齿苋提取物、溶液及其制备方法和应用 | |
CN101869587B (zh) | 一种从菱壳中提取抗胃癌活性成分的方法 | |
JP4880479B2 (ja) | キサントセラスソルビフォリア抽出物を含む組成物、該抽出物から単離された化合物、それを調製する方法、およびその使用方法 | |
CN102370707B (zh) | 桑叶和/或桑枝提取物的制备方法及所得产品和应用 | |
CN110041172A (zh) | 一种利用微生物处理大麻花叶提高大麻二酚提取率的工艺 | |
EP1859834B1 (en) | Anti-inflammatory agent | |
AU2012286357A1 (en) | Eucommia extract, preparation method therefor and use thereof | |
CN108530430B (zh) | 酯型儿茶素吡咯烷生物碱及其制备方法和应用 | |
CN105998103A (zh) | 板栗花活性提取物及其制备方法和应用 | |
CN113768843B (zh) | 一种用于化妆品的苦参提取物及其制备方法 | |
CN104706553B (zh) | 一种没药叶细胞提取物的提取方法及其应用 | |
CN114478196A (zh) | 一种从春榆根里提取补骨脂酚并纯化的方法及在化妆品中的应用 | |
CN113813265A (zh) | 灵芝酸a在治疗银屑病药物中的应用 | |
CN111228330A (zh) | 一种含千金藤碱的抗炎药物组合物及其制备方法 | |
CN102336803A (zh) | 七叶皂苷提取物的纯化制备方法 | |
CN102558128B (zh) | 含银杏原花青素提取物的制备方法 | |
CN112194704B (zh) | 一种甾体皂苷类化合物及其制备方法和应用 | |
CN109288902B (zh) | 一种具有强抗氧化活性的酸枣叶总黄酮发酵产物的制备方法及其应用 | |
CN109081842B (zh) | 一种深海真菌来源蒽醌类化合物及其在制备抗过敏药物中的应用 | |
CN109091602B (zh) | 韭菜子有效成分、提取方法及其在制备保护肝损伤药物方面的应用 | |
CN101186633B (zh) | 糙海参中皂苷类抗真菌化合物及其制备方法 | |
CN109528748A (zh) | 环磷酸腺苷盐在制备外用消脂减肥产品中的应用 | |
CN115068387B (zh) | 一种植物组合物及其在化妆品中的应用 | |
CN111675772B (zh) | 一种抑制黑色素合成的天然成分及在化妆品中的应用 | |
CN108997473A (zh) | 一种非海参烷型海参皂苷及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211221 |
|
RJ01 | Rejection of invention patent application after publication |